Research Discovery Finder | CHOP Research Institute
 
1 - 3 of 3

Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism (for children under 1 year of age)

Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism

This study is a randomized, double-blind, placebo-controlled study that will evaluate the safety and efficacy of dasiglucagon in children between the ages of 7 days and 12 months who have congenital hyperinsulinism.

Related PI: Diva D. De León-Crutchlow, MD, MSCE
Related Conditions: Hyperinsulinism, Hypoglycemia, Endocrinology Disorders, Insulin Dysfunction, Rare Disease, Rare Disorder Natural History Studies and Clinical Trials, Clinical Trials, Pediatric Endocrinology, Beta Cell Dysfunction, Rare Genetic Disorders, Pancreas Dysfunction

HM15136 for the Treatment of Congenital Hyperinsulinism Research Study

The purpose of this study is to look at the safety and tolerability (how well you will react) of the study drug (HM15136) and to determine if it is effective for the treatment of Congenital Hyperinsulinism (HI).

Related PI: Diva D. De León-Crutchlow, MD, MSCE
Related Conditions: Hyperinsulinism, Hypoglycemia, Endocrinology Disorders, Clinical Trials, Beta Cell Dysfunction, Pediatric Endocrinology, Rare Disorder Natural History Studies and Clinical Trials, Rare Disease, Insulin Dysfunction, Pancreas Dysfunction, Beta Cell Dysfunction

Phenotypes of Congenital Hyperinsulinism

Phenotypes of Congenital Hyperinsulinism

We are doing this study to see if the patterns of abnormalities in controlling insulin in children and adults with hyperinsulinism are related to any underlying genetic cause and to identify possible new genetic causes.

Related Conditions: Hyperinsulinism, Hypoglycemia, Endocrinology Disorders, Pancreas Dysfunction, Pancreatectomy, Genetic Disorders, Rare Disease, Rare Disorder Natural History Studies and Clinical Trials, Genetic Disease, Beta Cell Dysfunction, Pediatric Endocrinology
1 - 3 of 3